CN119523887A - 一种治疗手足皲裂的药膏及其制备方法 - Google Patents
一种治疗手足皲裂的药膏及其制备方法 Download PDFInfo
- Publication number
- CN119523887A CN119523887A CN202411797426.4A CN202411797426A CN119523887A CN 119523887 A CN119523887 A CN 119523887A CN 202411797426 A CN202411797426 A CN 202411797426A CN 119523887 A CN119523887 A CN 119523887A
- Authority
- CN
- China
- Prior art keywords
- ointment
- pedis
- treating
- skin
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 210000002683 foot Anatomy 0.000 claims abstract description 38
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 32
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 31
- 241000905957 Channa melasoma Species 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 16
- 229960001631 carbomer Drugs 0.000 claims abstract description 16
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 16
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims abstract description 16
- 229960002216 methylparaben Drugs 0.000 claims abstract description 16
- MRUMAIRJPMUAPZ-UHFFFAOYSA-N quinolin-8-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CN=C2C(O)=CC=CC2=C1 MRUMAIRJPMUAPZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000230 xanthan gum Substances 0.000 claims abstract description 13
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 13
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 13
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 13
- 239000008213 purified water Substances 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 30
- 235000011187 glycerol Nutrition 0.000 claims description 15
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 15
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 15
- 229940099259 vaseline Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 5
- 229960005150 glycerol Drugs 0.000 claims description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 6
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 2
- 239000004264 Petrolatum Substances 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 229940066842 petrolatum Drugs 0.000 abstract 1
- 235000019271 petrolatum Nutrition 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 20
- 241000700159 Rattus Species 0.000 description 14
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 10
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 10
- 229960002591 hydroxyproline Drugs 0.000 description 10
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 238000011552 rat model Methods 0.000 description 5
- 230000037380 skin damage Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 206010021198 ichthyosis Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010067197 Tinea manuum Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 101000975474 Homo sapiens Keratin, type I cytoskeletal 10 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 1
- 241000842539 Rhagades Species 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008743 palmoplantar keratosis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开一种防治手足皲裂的药膏及其制备方法，所述药膏包括以下组分：纯化水、凡士林、甘油、单硬脂酸甘油酯、黄原胶、卡波姆、羟苯甲酯、8‑羟基喹啉硫酸盐。本药膏在NaOH溶液构建的大鼠皲裂模型中，能有效的改善皮肤裂口、肿胀和出血。本发明能够起到润肤护肤和促进手足裂口愈合等效果，在治疗手足皲裂方面有独特的显著优势，适合大面积推广使用。
Description
技术领域
本发明涉及药膏领域，特别涉及一种防治手足皲裂的药膏及其制备方法。
背景技术
手足皲裂是指因各种原因导致的手足皮肤干燥、出现裂隙，常伴有疼痛，是一种常见的手足部皮肤病。正常人体掌跖部位皮肤角质层较厚且无皮脂腺，缺乏皮脂保护，在外因刺激下，角质层会变脆变硬，一旦牵拉受压超过皮肤正常承受限度即可皲裂致病。常见的诱发因素有干燥、摩擦、外伤、酸碱物质、有机溶媒（肥皂洗洁精）等。手足皲裂需与手足湿疹、掌跖角化症、手足癣及鱼鳞病相鉴别，亦可合并手足癣、湿疹、鱼鳞病等。
手足皲裂不仅会造成疼痛和不适，还会使人的外表变得粗糙、难看，影响美观。由于皮肤破裂，容易收集尘埃和细菌，给感染带来机会，导致皮肤红肿、化脓、发痒、疼痛等。会限制手脚的运动能力，影响运动和日常生活。手足皲裂患者一般都会对自己的手脚感到不自信，影响心理健康。
单纯手足皲裂可遵医嘱使用维生素 E 乳膏外涂或维生素 B6 口服以改善症状。合并其他疾病若合并有湿疹、鱼鳞病的患者来说，则建议其积极治疗原发病，可在医生指导下使用氢化可的松乳膏等糖皮质激素制剂或口服维生素 A 等。对于合并有湿疹、鱼鳞病等疾病的患者，需要针对原发病进行治疗。氢化可的松乳膏等糖皮质激素制剂可以减轻炎症和瘙痒，促进皮肤的修复。维生素 A 可以调节皮肤的角化过程，改善皮肤的干燥和粗糙。但是目前针对手足皲裂的药剂临床药效均不能令人满意，或长期使用有刺激性作用，因此发明一种治疗手足皲裂的药膏是本发明目的所在。
发明内容
针对现有技术中对治疗手足皲裂的膏剂药效不佳、有刺激性等问题，本发明提供一种防治手足皲裂的药膏及其制备方法。
为了实现上述目的，本发明具体采取了以下技术方案：
一种防治手足皲裂的药膏（记为ZZ001），按照重量份数计，组成如下：纯化水70~90%、凡士林1~10%、甘油1~10%、单硬脂酸甘油酯1~10%、黄原胶0.1~1%、卡波姆0.1~1%、羟苯甲酯0.1~1% 、8-羟基喹啉硫酸盐0.1~1%。
所述的治疗皲裂药膏（ZZ001）的制备过程为：
(1)按比例称取凡士林、单硬脂酸甘油酯、甘油投入容器内加热至80~85℃,搅拌至完全溶解，作为油相；
(2) 按比例称取水、黄原胶、卡波姆、羟苯甲酯、8-羟基喹啉硫酸盐投入容器内加热至80~85℃，搅拌至完全溶解，作为水相；
(3)搅拌下将步骤(1)油相加入步骤(2)水相中，搅拌均匀；降温至室温即可。
优选地，步骤（3）中，先以20~100 r/min的搅拌速度将步骤(1)油相加入步骤(2)水相中，后再以5000~10000r/min的搅拌速度搅拌均匀（1~10分钟）。
上述防治手足皲裂的药膏作为防治手足皲裂药物的应用。
手足皲裂的动物模型中观察ZZ001的作用，发现可以缓解手足皲裂的临床症状。
手足皲裂的动物模型是采用NaOH溶液涂抹的方式。采用此模型观察ZZ001对手足皲裂的治疗作用。结果显示ZZ001有效改善NaOH溶液涂抹导致的皮肤裂口，诱导伤口愈合。
附图说明
图1为ZZ001对皲裂大鼠模型治疗效果的大体形态观察；
图2为ZZ001对大鼠模型皮肤损伤的评分及统计学分析；
图3为ZZ001大鼠模型皮肤HYP（羟脯氨酸）的影响；
图2、图3中，*、**、*** 和 **** 分别表示p<0.05、p<0.01、p<0.001和p<0.0001。
具体实施方式
为了使本发明的技术目的、技术方案和有益效果更加清楚，下面结合具体实施例对本发明的技术方案作出进一步的说明，但所述实施旨在解释本发明，而不能理解为对本发明的限制，实施例中未注明具体技术或条件者，按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。
实施例1、一种防治手足皲裂的药膏（记为ZZ001）及制备工艺
以质量百分比计，ZZ001配方如下：纯化水88.2%、凡士林2%、甘油3%、单硬脂酸甘油酯6%、黄原胶0.2%、卡波姆0.1%、羟苯甲酯0.2% 、8-羟基喹啉硫酸盐0.3%。
所述的治疗皲裂药膏的制备过程为：
(1)按比例称取凡士林、单硬脂酸甘油酯、甘油投入容器内加热至80~85℃,搅拌至完全溶解,作为油相；
(2)水、黄原胶、卡波姆、羟苯甲酯、8-羟基喹啉硫酸盐投入适当容器内加热至80~85℃,搅拌至完全溶解,作为水相；
(3)开启搅拌，搅拌速度为20r/min，将步骤(1) 80~85℃的油相缓缓加入步骤(2)80~85℃的水相中，将搅拌速度调为40r/min，搅拌20s~1min，开均质器, 8000r/min均质3min；
降温至室温即可。
实施例2、一种防治手足皲裂的药膏（记为ZZ001）及制备工艺
以质量百分比计，ZZ001配方如下：纯化水70%、凡士林10%、甘油10%、单硬脂酸甘油酯6%、黄原胶1%、卡波姆1%、羟苯甲酯1%、8-羟基喹啉硫酸盐1%。
所述的治疗皲裂药膏的制备过程为：
(1)按比例称取凡士林、单硬脂酸甘油酯、甘油投入容器内加热至80~85℃,搅拌至完全溶解,作为油相；
(2)水、黄原胶、卡波姆、羟苯甲酯、8-羟基喹啉硫酸盐投入适当容器内加热至80~85℃,搅拌至完全溶解,作为水相；
(3)开启搅拌，搅拌速度为20r/min，将步骤(1) 80~85℃的油相缓缓加入步骤(2)80~85℃的水相中，将搅拌速度调为40r/min，搅拌20s~1min，开均质器, 8000r/min均质5min；
降温至室温即可。
实施例3、一种防治手足皲裂的药膏（记为ZZ001）及制备工艺
以质量百分比计，ZZ001配方如下：纯化水90%、凡士林1%、甘油1%、单硬脂酸甘油酯7.6 %、黄原胶0.1%、卡波姆0.1%、羟苯甲酯0.1% 、8-羟基喹啉硫酸盐0.1%。
所述的治疗皲裂药膏的制备过程为：
(1)按比例称取凡士林、单硬脂酸甘油酯、甘油投入容器内加热至80~85℃,搅拌至完全溶解,作为油相；
(2)水、黄原胶、卡波姆、羟苯甲酯、8-羟基喹啉硫酸盐投入适当容器内加热至80~85℃,搅拌至完全溶解,作为水相；
(3)开启搅拌，搅拌速度为20r/min，将步骤(1) 80~85℃的油相缓缓加入步骤(2)80~85℃的水相中，将搅拌速度调为40r/min，搅拌20s~1min，开均质器, 8000r/min均质2min；
降温至室温即可。
应用例1、ZZ001对皲裂大鼠模型治疗效果的大体形态观察
实验动物为6周龄的雌性SD大鼠，购自斯贝福（北京）生物技术有限公司。待大鼠适应1周后，留取5只大鼠作为空白组，其余大鼠作为模型组建模。所有大鼠用水合氯醛麻醉后用脱毛膏脱去背部毛发，退毛面积约3*3cm。退完毛的建模大鼠用0.5M浓度的NaOH溶液涂抹背部皮肤，每次涂抹约1mL。该操作每天进行1次。5-7天后大鼠背部皮肤开裂、肿胀、结痂后作为建模成功的标志，空白组大鼠仅退毛不做任何处理。
建模成功后大鼠随机分为3组，每组5只。分别是模型组、ZZ001组（实施例1制得）和阳性药组，阳性药采用市售的马应龙尿素软膏。ZZ001组和尿素软膏组每天涂抹两次，每次0.3g，模型组每天涂抹生理盐水，每次1mL。
结果如图1所示，与空白对照组相比，模型组显示出典型的皲裂特征，如皮肤裂口，出血，肿胀，组织液渗出，结痂等，给药组与阳性药组均显示出能显著缓解这些皮肤损伤，只表现出个别出血点和结痂。
应用例2、ZZ001对大鼠模型皮肤损伤的评分及统计学分析
每天目测评价皮损修复情况，记录数据。皮损评分标准如下： 0 分：皮损完全消失；1 分：皮损修复面积达 1/2～1；2 分：皮损修复面积达 1 /4 ～ 1 /2；3 分：皮损修复面积达 0～1 /4。
结果如图2所示，模型组显示出较高的皮肤损伤，皮损面积较大，且自体恢复能力极差，而ZZ001组和阳性药组能极大的缓解NaOH诱导的皮肤损伤。
应用例3、ZZ001对皲裂大鼠模型皮肤羟脯氨酸（HYP）含量的影响
试验结束后收取大鼠背部皮肤样本，每组每只大鼠剪取涂药处皮肤50mg，采用南京建成生物科技有限公司的羟脯氨酸（HYP）测定试剂盒（碱水解法）测定大鼠背部皮肤羟脯氨酸（Hyp）含量。结果如图3显示，与正常（空白对照）组小鼠相比，在NaOH溶液的持续刺激下，模型对照组大鼠皮肤的HYP显著下降，皮肤表层出现较大损伤，且皮肤的愈合能力和愈合速度显著下降，而给药组和阳性对照组的HYP则显著升高，接近空白组的含量，说明在ZZ001和阳性药的处理下，皮肤愈合速度增加，在试验结束时已经接近正常皮肤，ZZ001的HYP含量高于阳性药尿素软膏的HYP含量。说明ZZ001的效果要好于阳性对照。
综上结果表明，ZZ001具有缓解手足皲裂的临床症状，改善皮肤裂口，诱导伤口愈合的作用。在治疗手足皲裂病方面显示了良好的应用前景。
Claims (4)
1.一种防治手足皲裂的药膏，其特征在于，按照重量份数计，组成如下：纯化水70~90%、凡士林1~10%、甘油1~10%、单硬脂酸甘油酯1~10%、黄原胶0.1~1%、卡波姆0.1~1%、羟苯甲酯0.1~1% 、8-羟基喹啉硫酸盐0.1~1%。
2.根据权利要求1所述的防治手足皲裂的药膏的制备方法，其特征在于，过程如下：
(1)按比例称取凡士林、单硬脂酸甘油酯、甘油投入容器内加热至80~85℃,搅拌至完全溶解，作为油相；
(2) 按比例称取水、黄原胶、卡波姆、羟苯甲酯、8-羟基喹啉硫酸盐投入容器内加热至80~85℃，搅拌至完全溶解，作为水相；
(3)搅拌下将步骤(1)油相加入步骤(2)水相中，搅拌均匀；降温至室温即可。
3.根据权利要求1所述的防治手足皲裂的药膏的制备方法，其特征在于，步骤（3）中，先以20~100 r/min的搅拌速度将步骤(1)油相加入步骤(2)水相中，后再以5000~10000r/min的搅拌速度搅拌均匀。
4.权利要求1所述防治手足皲裂的药膏作为防治手足皲裂药物的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411797426.4A CN119523887A (zh) | 2024-12-09 | 2024-12-09 | 一种治疗手足皲裂的药膏及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411797426.4A CN119523887A (zh) | 2024-12-09 | 2024-12-09 | 一种治疗手足皲裂的药膏及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119523887A true CN119523887A (zh) | 2025-02-28 |
Family
ID=94698693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411797426.4A Pending CN119523887A (zh) | 2024-12-09 | 2024-12-09 | 一种治疗手足皲裂的药膏及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119523887A (zh) |
-
2024
- 2024-12-09 CN CN202411797426.4A patent/CN119523887A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769654A (zh) | 一种舒敏护肤组合物及其在化妆品中的应用 | |
| JPH04501122A (ja) | ▲ざ▼瘡又は乾癬に関する皮膚の治療のための化合物及び方法 | |
| CN105596277A (zh) | 一种治疗痤疮的仙人掌面霜及制备方法 | |
| CN113018250A (zh) | 一种天然药物的外用制剂、制备方法及其应用 | |
| CN105943666B (zh) | 一种用于婴幼儿敏感肌肤护理的组合物及其制备方法 | |
| US20140178487A1 (en) | Camel hump oil - based herbal compositions and method of making the same | |
| CN102423342B (zh) | 防治皮肤湿疹和瘙痒症的药物组合物及剂型和应用 | |
| CN110974861A (zh) | 一种艾纳香油脂质体 | |
| JPH10120558A (ja) | 津液改善用皮膚外用剤 | |
| CN103977110A (zh) | 一种治疗牛皮癣植物软膏及其制备方法 | |
| CN110038056A (zh) | 一种治疗宠物肢体炎性肿胀的复方五倍子软膏及其制备方法 | |
| Qureshi et al. | Clinical observation of Unani medicine in the treatment of Psoriasis: A Case Study | |
| CN107693437A (zh) | 防皲裂的润肤滋养霜 | |
| CN1247227C (zh) | 一种治疗螨虫感染性皮肤疾病的外用脂质体制剂 | |
| CN107158051A (zh) | 一种治疗湿疹的鞣酸软膏及其制备方法 | |
| CN116832086B (zh) | 一种治疗皮肤皲裂的外用中药组合物及其用途 | |
| CN105168360A (zh) | 一种治疗痤疮、粉刺的植物提取物复方擦剂及其制备方法 | |
| CN119280312B (zh) | 一种治疗银屑病的中药组合物及其制备方法与应用 | |
| US20130287859A1 (en) | Method for treating prupritus with cartilage extract | |
| KR100502069B1 (ko) | 홍삼 조사포닌을 함유하는 여드름 개선용 부직포 팩 | |
| CN119868435B (zh) | 治疗陈旧性踝关节扭伤的中药组合物和中药膏摩剂 | |
| CN112915084B (zh) | 一种治疗老年性皮肤瘙痒症的药物组合物及外用制剂 | |
| RU2705162C1 (ru) | Мазь для лечения псориаза (варианты) | |
| EP1688145A1 (en) | Methods and compositions for treating psoriasis | |
| CN100493606C (zh) | 人溶菌酶在制备治疗瘙痒症的药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |